行情

CLRB

CLRB

Cellectar
NASDAQ

实时行情|Nasdaq Last Sale

1.175
-0.065
-5.24%
盘后: 1.175 0 0.00% 16:00 04/03 EDT
开盘
1.250
昨收
1.240
最高
1.254
最低
1.150
成交量
2.38万
成交额
--
52周最高
3.330
52周最低
1.040
市值
1,104.03万
市盈率(TTM)
-0.5899
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CLRB价格均价为6.35,最高价位10.00,最低价为3.000。

EPS

CLRB 新闻

更多
  • Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update
  • GlobeNewswire · 03/09 13:00
  • Cellectar Biosciences Q4 EPS $(0.33) Down From $0.06 YoY
  • Benzinga · 03/09 12:03
  • VIAC, WIX among premarket losers
  • Seeking Alpha - Article · 02/20 14:17
  • GRPN, SLS, ENPH and SSTI among midday movers
  • Seeking Alpha - Article · 02/19 17:42

所属板块

制药
-0.14%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

CLRB 简况

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
展开

微牛提供Cellectar Biosciences Inc(NASDAQ-CLRB)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CLRB股票新闻,以帮助您做出投资决策。